JP2024502615A - チェックポイント阻害剤抵抗性のがんを治療するためのセネカバレーウイルス併用療法 - Google Patents

チェックポイント阻害剤抵抗性のがんを治療するためのセネカバレーウイルス併用療法 Download PDF

Info

Publication number
JP2024502615A
JP2024502615A JP2023541664A JP2023541664A JP2024502615A JP 2024502615 A JP2024502615 A JP 2024502615A JP 2023541664 A JP2023541664 A JP 2023541664A JP 2023541664 A JP2023541664 A JP 2023541664A JP 2024502615 A JP2024502615 A JP 2024502615A
Authority
JP
Japan
Prior art keywords
cancer
svv
inhibitor
checkpoint inhibitor
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502615A5 (enExample
Inventor
ハレンベック、ポール、エル．
チャダ、スニル
Original Assignee
セネカ セラピューティクス、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セネカ セラピューティクス、インク． filed Critical セネカ セラピューティクス、インク．
Publication of JP2024502615A publication Critical patent/JP2024502615A/ja
Publication of JP2024502615A5 publication Critical patent/JP2024502615A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023541664A 2021-01-11 2022-01-11 チェックポイント阻害剤抵抗性のがんを治療するためのセネカバレーウイルス併用療法 Pending JP2024502615A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163135914P 2021-01-11 2021-01-11
US63/135,914 2021-01-11
PCT/US2022/011994 WO2022150769A1 (en) 2021-01-11 2022-01-11 Seneca valley virus combination therapy to treat a cancer refractory to a checkpoint inhibitor

Publications (2)

Publication Number Publication Date
JP2024502615A true JP2024502615A (ja) 2024-01-22
JP2024502615A5 JP2024502615A5 (enExample) 2025-01-21

Family

ID=82357000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541664A Pending JP2024502615A (ja) 2021-01-11 2022-01-11 チェックポイント阻害剤抵抗性のがんを治療するためのセネカバレーウイルス併用療法

Country Status (9)

Country Link
US (1) US20240100107A1 (enExample)
EP (1) EP4274593A4 (enExample)
JP (1) JP2024502615A (enExample)
KR (1) KR20230130689A (enExample)
CN (1) CN116782941A (enExample)
AU (1) AU2022205429A1 (enExample)
CA (1) CA3207860A1 (enExample)
IL (1) IL304170A (enExample)
WO (1) WO2022150769A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017096201A1 (en) 2015-12-02 2017-06-08 Memorial Sloan-Kettering Cancer Center Seneca valley virus (svv) cellular receptor targeted oncotherapy
WO2021016194A1 (en) 2019-07-19 2021-01-28 Racaniello Vincent R Second generation seneca valley virus oncolytic therapy: compositions and methods thereof
WO2022159508A1 (en) * 2021-01-19 2022-07-28 Seneca Therapeutics, Inc. Armed seneca valley virus oncolytic therapy compositions and methods thereof
WO2024054989A1 (en) * 2022-09-08 2024-03-14 Seneca Therapeutics, Inc. Cancer therapies with oncolytic virus and an immune checkpoint inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210711A1 (en) * 2019-04-11 2020-10-15 Seneca Therapeutics, Inc. Compositions and methods of using seneca valley virus (svv) for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638318B2 (en) * 2003-09-26 2009-12-29 Norvartis Ag Seneca Valley virus based compositions and methods for treating disease
DK3552615T3 (da) * 2014-07-16 2022-02-14 Transgene Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
WO2017096201A1 (en) * 2015-12-02 2017-06-08 Memorial Sloan-Kettering Cancer Center Seneca valley virus (svv) cellular receptor targeted oncotherapy
EP3419643A4 (en) * 2016-02-24 2020-04-01 Children's Hospital of Eastern Ontario Research Institute Inc. SMC COMBINATION THERAPY FOR TREATING CANCER
TW201825511A (zh) * 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210711A1 (en) * 2019-04-11 2020-10-15 Seneca Therapeutics, Inc. Compositions and methods of using seneca valley virus (svv) for treating cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHARLES M. RUDIN ET AL.: "Phase I Clinical Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Ad", CLINICAL CANCER RESEARCH, vol. 17, no. 4, JPN6025045116, 2011, pages 888 - 895, ISSN: 0005723083 *
FUXIAO LIU ET AL.: "Construction of eGFP-Tagged Senecavirus A for Facilitating Virus Neutralization Test and Antiviral A", VIRUSES, vol. 12, no. 3, JPN6025045117, 2020, pages 283 - 1, ISSN: 0005839062 *

Also Published As

Publication number Publication date
WO2022150769A1 (en) 2022-07-14
AU2022205429A1 (en) 2023-07-20
EP4274593A4 (en) 2025-06-25
CN116782941A (zh) 2023-09-19
EP4274593A1 (en) 2023-11-15
KR20230130689A (ko) 2023-09-12
US20240100107A1 (en) 2024-03-28
CA3207860A1 (en) 2022-07-14
IL304170A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
AU2023282170B2 (en) Preservation of immune response during chemotherapy regimens
US20240100107A1 (en) Seneca valley virus combination therapy to treat a cancer refractory to a checkpoint inhibitor
AU2016244262B2 (en) Combination therapy for the treatment of glioblastoma
AU2008290442B2 (en) Antitumour combinations containing a VEGF inhibiting agent and Irinotecan
KR20220035931A (ko) 2세대 세네카 밸리 바이러스 종양용해 요법: 이의 조성물 및 방법
KR20130092617A (ko) 암 치료에 사용하기 위한 베무라페닙 및 인터페론을 포함하는 병용 요법
US20240307470A1 (en) Armed seneca valley virus oncolytic therapy compositions and methods thereof
WO2021178449A1 (en) Compositions and methods for the treatment of pancreatic cancer
US20260083819A1 (en) Compositions, systems, and methods for treating cancer using tumor treating fields (ttfields) and interferon gamma
RU2779478C2 (ru) Сохранение иммунного ответа во время химиотерапевтических схем
AU2021200121A1 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
EA043297B1 (ru) Применение ингибитора cdk4/6 в сохранении иммунного ответа во время химиотерапевтических схем
HK1141241A (en) Antitumour combinations containing a vegf inhibiting agent and irinotecan

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250110

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260414